incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-09. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
As (R)-MDMA is less neurotoxic than (S)-MDMA and MDMA or even non-neurotoxic, it may allow for greater clinical viability and prolonged regimens of drug-assisted psychotherapy. (R)-MDMA and (S)-MDMA have shown equivalent effects in terms of inducing prosocial behavior in monkeys. However, (S)-MDMA shows higher potency, whereas (R)-MDMA shows greater maximal effects. Conversely, (S)-MDMA does not increase prosocial behavior in mice, whereas both MDMA and (R)-MDMA do so. MDMA and (S)-MDMA increase locomotor activity, a measure of psychostimulant-like effect, in rodents, whereas (R)-MDMA does not do so. (R)-MDMA likewise showed fewer reinforcing effects than (S)-MDMA in non-human primates. These findings further add to (R)-MDMA showing reduced psychostimulant-like and addictive effects compared to MDMA and (S)-MDMA.
=== Recruiting and activating of immune cells === The binding of a BsAb to its target antigens can lead to a variety of effects. The most widely used application of this approach is in cancer immunotherapy, where BsAbs are engineered to simultaneously bind a cytotoxic cell and a target (a tumour cell) to be destroyed. It is possible to observe the bridging effect that BsAbs have on T cell/cancer cell interactions using label-free live cell imaging. Catumaxomab, one of the first trifunctional antibodies approved for therapeutic use, binds both CD3 on cytotoxic T cells and EpCAM on human adenocarcinomas. The Fc region additionally binds to a cell that expresses Fc receptors, like a macrophage, natural killer cell or dendritic cell. Since the Fc region is still intact, this allows for the BsAb to trigger common immune responses when recognized by an Fc receptor, such as antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity.
== Prediction == There are many situations where prediction of partition coefficients prior to experimental measurement is useful. For example, tens of thousands of industrially manufactured chemicals are in common use, but only a small fraction have undergone rigorous toxicological evaluation. Hence there is a need to prioritize the remainder for testing. QSAR equations, which in turn are based on calculated partition coefficients, can be used to provide toxicity estimates. Calculated partition coefficients are also widely used in drug discovery to optimize screening libraries and to predict druglikeness of designed drug candidates before they are synthesized. As discussed in more detail below, estimates of partition coefficients can be made using a variety of methods, including fragment-based, atom-based, and knowledge-based that rely solely on knowledge of the structure of the chemical. Other prediction methods rely on other experimental measurements such as solubility. The methods also differ in accuracy and whether they can be applied to all molecules, or only ones similar to molecules already studied.
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
Sources: en.wikipedia.org
James William Middleton (born 15 April 1987) is a British entrepreneur who is the younger brother of Catherine, Princess of Wales. Born in Reading, Berkshire, Middleton was educated at St Andrew's School, Pangbourne. He briefly attended the University of Edinburgh before dropping out and founding a cake-making business. Middleton began receiving media attention during his eldest sister's relationship with and subsequent marriage to Prince William. He is a mental health advocate and has spoken about his experiences with major depressive disorder. Middleton is also an ambassador for the Pets As Therapy charity.
== Further reading == Aziz, Nusrate; Asadullah, M Niaz (2017). "Military spending, armed conflict and economic growth in developing countries in the post–Cold War era". Journal of Economic Studies. 44 (1): 47–68. Bartel, Fritz (2022). The Triumph of Broken Promises: The End of the Cold War and the Rise of Neoliberalism. Harvard University Press. ISBN 9780674976788. Henriksen, Thomas H. (2017). Cycles in US Foreign Policy Since the Cold War. Palgrave Macmillan. Jones, Bruce D.; Stedman, Stephen John (2017). "Civil Wars & the Post–Cold War International Order". Dædalus. 146 (4): 33–44. Menon, Rajan; Rumer, Eugene B., eds. (2015). Conflict in Ukraine: The Unwinding of the Post–Cold War Order. MIT Press. Peterson, James W. (2017). Russian-American relations in the post–Cold War world. Oxford UP. Sakwa, Richard (2017). Russia against the Rest: The Post–Cold War Crisis of World Order. Cambridge UP. p. 362. Wood, Luke B. (2017). "The politics of identity and security in post–Cold War Western and Central Europe". European Politics and Society. 18 (4): 552–556.
== Early life and education == Schmitt was born in Bridgeton, Missouri, a suburb of St. Louis. He graduated from DeSmet Jesuit High School in 1993 and from Truman State University in 1997, with a BA in political science. At Truman, Schmitt was a member of the Alpha Kappa Lambda fraternity, played football and baseball, and was a founding member of Truman's Habitat for Humanity chapter. He received a scholarship to attend Saint Louis University School of Law, where he earned his JD in 2000.
=== Rota-Stabelli et al. (2013) === In 2013 Rota-Stabelli et al. used the signal in the 62 protein-coding genes assembled by Regier et al. in 2010 to improve the knowledge of the internal relationship in the Pancrustacea group. This data set infers a highly supported nucleotide tree that is substantially different from the corresponding, but poorly supported, amino acid one. The discrepancy between the nucleotide-based and the amino acids-based trees is caused by substitutions within synonymous codon families (especially those of serine-TCN and AGY): different arthropod lineages are differentially biased in their usage of serine, arginine, and leucine synonymous codons, and the serine bias is correlated with the topology derived from the nucleotides, but not the amino acids. The authors suggest that a parallel, partially compositionally driven, synonymous codon-usage bias affects the nucleotide topology. As substitutions between serine codon families can proceed through threonine or cysteine intermediates, amino acid data sets might also be affected by the serine codon-usage bias. The analyses suggests that a Dayhoff recoding strategy would partially ameliorate the effects of such bias. Although amino acids provide an alternative hypothesis of pancrustacean relationships, neither the nucleotides nor the amino acids version of this data set bring enough genuine phylogenetic information to robustly resolve the relationships within group, which should still be considered unresolved.
...Had Sony stuck with the original plan of a scaled-down superhero franchise, one that really was rooted in romantic drama, they would have at least stuck out in a crowded field of superhero franchises. When every superhero film is now going bigger, Amazing Spider-Man could have distinguished itself by going small and intimate." This would have saved Sony "a boatload of money", and potentially reversed the film's relative financial failure.
Sources: en.wikipedia.org
The cellular response in signal transduction cascades involves alteration of the expression of effector genes or activation/inhibition of targeted proteins. Regulation of protein activity mainly involves phosphorylation/dephosphorylation events, leading to its activation or inhibition. It is the case for the vast majority of responses as a consequence of the binding of the primary messengers to membrane receptors. This response is quick, as it involves regulation of molecules that are already present in the cell. On the other hand, the induction or repression of the expression of genes requires the binding of transcriptional factors to the regulatory sequences of these genes. The transcriptional factors are activated by the primary messengers, in most cases, due to their function as nuclear receptors for these messengers. The secondary messengers like DAG or Ca2+ could also induce or repress gene expression, via transcriptional factors. This response is slower than the first because it involves more steps, like transcription of genes and then the effect of newly formed proteins in a specific target. The target could be a protein or another gene.
CCPs can be a valuable resource of genetic material. They can be used to preserve valuable genetic diversity for future use, or as base for new breeding programs. Promising plants can be selected and multiplied, generating new varieties. It is legal under EU law to sell and buy seeds from a composite cross population as an experiment in the period between 2014 and 2018. In 2000, with the help of plant breeders and the Organic Research Centre, the scientist Martin Wolfe crossed 20 varieties of wheat (selected for quality and yield) and crossed them to obtain 190 new crosses. These seeds were not further selected and planted, grown, harvested and reseeded together as a population. Martin Wolfe called it YQ, for "yield" and "quality". Wolfe lobbied in Brussels and Westminster to receive an exception to the EU regulations that would allow YQ to be sold. In 2014, it was accepted and since 2017 the YQ seed, officially called the "ORC Wakelyns Population" was the first population wheat to go on sale in Europe.
=== Radiometric dating === Two radiometric dating methods involve thorium isotopes: uranium–thorium dating, based on the decay of 234U to 230Th, and ionium–thorium dating, which measures the ratio of 232Th to 230Th. These rely on the fact that 232Th is a primordial radioisotope, but 230Th only occurs as an intermediate decay product in the decay chain of 238U. Uranium–thorium dating is a relatively short-range process because of the short half-lives of 234U and 230Th relative to the age of the Earth: it is also accompanied by a sister process involving the alpha decay of 235U into 231Th, which very quickly becomes the longer-lived 231Pa, and this process is often used to check the results of uranium–thorium dating. Uranium–thorium dating is commonly used to determine the age of calcium carbonate materials such as speleothem or coral, because uranium is more soluble in water than thorium and protactinium, which are selectively precipitated into ocean-floor sediments, where their ratios are measured. The scheme has a range of several hundred thousand years. Ionium–thorium dating is a related process, which exploits the insolubility of thorium (both 232Th and 230Th) and thus its presence in ocean sediments to date these sediments by measuring the ratio of 232Th to 230Th. Both of these dating methods assume that the proportion of 230Th to 232Th is a constant during the period when the sediment layer was formed, that the sediment did not already contain thorium before contributions from the decay of uranium, and that the thorium cannot migrate within the sediment layer.
=== Tokusou Combinations === Dekaranger Robo (デカレンジャーロボ, Dekarenjā Robo): The Dekarangers' first giant robot composed of the five main Deka Machines that wields the Signal Cannon, which allows it to perform the Justice Flasher (ジャスティスフラッシャー, Jasutisu Furasshā) finisher, and the Judgement Sword, which allows it to perform the Judgement Crash (ジャッジメントクラッシュ, Jajjimento Kurasshu) finisher. Super Dekaranger Robo (スーパーデカレンジャーロボ, Gattai Sūpā Dekarenjā Robo): The Super Tokusou Combination (超特捜合体, Chō Tokusō Gattai) of Dekaranger Robo and the Deka Bike that is equipped with a series of boosters. Its finishers are the Gatling Punch (ガトリングパンチ, Gatoringu Panchi) and the Dynamite Upper (ダイナマイトアッパー, Dainamaito Appā). Dekaranger Robo Full Blast Custom (デカレンジャーロボ フルブラストカスタム, Dekarenjā Robo Furu Burasuto Kasutamu): A combination of Dekaranger Robo and the Blast Buggy that wields the Blast Launcher (ブラストランチャー, Burasuto Ranchā) and the Blast Shield (ブラストシールド, Burasuto Shīrudo), which allows it to perform the Spinning Blast (スピニングブラスト, Supiningu Burasuto) attack. The Blast Launcher and Shield can also combine to form the Full Blast Launcher (フルブラストランチャー, Furu Burasuto Ranchā), which allows Dekaranger Robo to perform the Full Blast (フルブラスト, Furu Burasuto) finisher. This formation appears exclusively in the film Tokusou Sentai Dekaranger The Movie: Full Blast Action.
==== Maryland Blue Ribbon Schools ==== Beacon Heights Elementary School, Riverdale, 2003–04 Bond Mill Elementary School, Laurel (year N/A) Columbia Park Elementary School, Landover, 1987–88 Fort Foote Elementary School, Fort Washington, 2000–01 Glenarden Woods Elementary School, Glenarden, 2005–06 Greenbelt Center Elementary School, Greenbelt, 1991–92 Heather Hills Elementary School, Bowie, 1989–90 & 2006–07 Rockledge Elementary School, Bowie, 1997–98 Whitehall Elementary School, Bowie, 2011–12 Templeton Elementary School, Riverdale, 1998–99 Kenmoor Middle School, Landover, 1988–89 Dora Kennedy French Immersion, Greenbelt, 2013–14 Kettering Middle School, Upper Marlboro, 1992–93 Martin Luther King, Jr. Middle School, Beltsville, 1992–93 Eleanor Roosevelt High School, Greenbelt, 1990–91 & 1997–98 Suitland High School, Forestville, 1988–89
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.